STOCK TITAN

Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB) will release its third quarter 2023 financial results on November 2, 2023. A conference call with investors will be held at 8:00 a.m. ET. The webcast replay will be available on the Seres website for approximately 21 days.
Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will release third quarter 2023 financial results on Thursday, November 2, 2023. Management will host a conference call with investors to discuss the results and corporate updates at 8:00 a.m. ET.

The conference call may be accessed by calling 1-866-777-2509 (international callers dial 1-412-317-5413). Participants may pre-register for the conference call at https://dpregister.com/sreg/10184132/faf729b9c0

To join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com.

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Seres’ lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiome therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation. The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit www.serestherapeutics.com.

Seres IR and PR Contact:

Kevin Mannix

kmannix@serestherapeutics.com

Source: Seres Therapeutics, Inc.

Seres Therapeutics will release its third quarter 2023 financial results on November 2, 2023.

The conference call with investors will be held at 8:00 a.m. ET.

The conference call can be accessed by calling 1-866-777-2509 (international callers dial 1-412-317-5413). Participants may also pre-register for the conference call at https://dpregister.com/sreg/10184132/faf729b9c0.

The webcast replay will be available on the Seres website in the 'Investors and News' section. It will be archived for approximately 21 days.
Seres Therapeutics Inc

NASDAQ:MCRB

MCRB Rankings

MCRB Latest News

MCRB Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Cambridge

About MCRB

seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.